MedTrace Logo

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07675824 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 271

Last updated 2026-06-30

No results posted yet for this study

Summary

This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP).

REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure.

The study is looking at:

* What side effects REGN22530 might cause
* How much REGN22530 is in the blood and eye fluid at different times
* If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well)
* How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others
* How well REGN22530 works

Conditions

  • Primary Open Angle Glaucoma (POAG)
  • Ocular Hypertension (OHT)

Interventions

DRUG

REGN22530

Administered per the protocol

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-23
Primary Completion
2029-07-25
Completion
2029-10-16
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07675824 on ClinicalTrials.gov